The first trial of a Zoloft birth defects lawsuit, originally set to begin in September 2014, has been delayed. The federal judge presiding over the national Zoloft multidistrict litigation recently reset the trial date to no later than October 13, 2014, so long as all appropriate discovery is completed by that date.
Hon. Cynthia Rufe, of the Unites States District Court for the Eastern District of Pennsylvania in Philadelphia, PA, entered a Pretrial Order amending her earlier Order governing the discovery and scheduling of the Zoloft MDL. Her Order address issues relating to document discovery of Pfizer, deposition discovery of Pfizer, interrogatories and requests for admission to Pfizer, and general causation “Daubert” motions.
The new Zoloft MDL litigation schedule addressed who would be included in the Initial Discovery Group and issues related to Threshold Plaintiffs Discovery. Judge Rufe ruled that the Court will identify the those cases that will be included in the Initial Discovery Group by separate Order. She ordered that discovery from Plaintiffs in the Initial Discovery Group be limited to Threshold Discovery and set out what information could be included. She extended the deadline by which Plaintiffs in the Initial Discovery Group must respond to the expanded Plaintiff’s Fact Sheet to April 22, 2013, and ordered Pfizer to respond to Defendant Fact Sheets by May 28, 2013, in a form to be agreed upon and set forth in a separate Order for Plaintiffs in the Initial Discovery Group. Finally, Judge Rufe identified whose depositions may be taken.
With regard to the initial trial setting, Judge Rufe ordered as follows:
8. INITIAL TRIAL SETTING: The first trial is tentatively set to begin no later than October 13, 2014, subject to the completion of all appropriate discovery and subject to further Order of the Court. However, the first trial will not commence less than eight months after completion of generic causation Daubert briefing. By January 11, 2013, the parties shall submit joint or competing proposals governing selection of Initial Discovery Group Cases. By April 15, 2013, the parties shall submit joint or competing proposals governing: (1) selection of Trial Pool Cases, (2) the scope of general causation Daubert, (3) scheduling of summary judgment and specific causation Daubert motions in Trial Pool Cases, and (4) protocol for selection and scheduling of the first cases to be tried.
Zoloft lawsuits included in the MDL claim that drug company Pfizer failed to warn of birth defects risks linked to use of the SSRI antidepressant during pregnancy. Despite Zoloft pregnancy risks, suits claim that Pfizer targeted marketing efforts to encourage doctors to prescribe Zoloft to pregnant women and women of child-bearing age who could become pregnant. In 2007, Zoloft became the most prescribed antidepressant drug in the U.S. with almost 30 million prescriptions filled. As a result, millions of unborn children have been put at risk of suffering Zoloft birth defects.
If you took Zoloft during pregnancy and your child was born with a birth defect, our experienced Zoloft litigation attorneys would like to speak with you about your legal rights, options, and potential claim to substantial financial compensation. Our lawyers help families across the U.S. on Zoloft birth defects claims. Let us help you. Contact us today for a free consultation with a top Zoloft lawyer.